1-3 of 3
Christopher K. Rushton
Close
Sort by
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors

Vignesh Shanmugam, Jeffrey W. Craig, Laura K. Hilton, Matthew H. Nguyen, Christopher K. Rushton, Kian Fahimdanesh, Scott Lovitch, Ben Ferland, David W. Scott, Jon C. Aster
Journal: Blood Advances
Blood Adv (2021) 5 (1): 71–83.
https://doi.org/10.1182/bloodadvances.2020002995
Published: 2021
Includes: Supplemental data
Journal Articles

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

Christopher K. Rushton, Sarah E. Arthur, Miguel Alcaide, Matthew Cheung, Aixiang Jiang, Krysta M. Coyle, Kirstie L. S. Cleary, Nicole Thomas, Laura K. Hilton, Neil Michaud, Scott Daigle, Jordan Davidson, Kevin Bushell, Stephen Yu, Ryan N. Rys, Michael Jain, Lois Shepherd, Marco A. Marra, John Kuruvilla, Michael Crump, Koren Mann, Sarit Assouline, Joseph M. Connors, Christian Steidl, Mark S. Cragg, David W. Scott, Nathalie A. Johnson, Ryan D. Morin
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2886–2898.
https://doi.org/10.1182/bloodadvances.2020001696
Published: 2020
Includes: Supplemental data